Telemedicine and Clinical Outcomes in Peritoneal Dialysis: A Propensity-Matched Study

Author:

Xu Xiao,Ma Tiantian,Tian Xue,Li Shaomei,Pei Huaying,Zhao Jinghong,Zhang Ying,Xiong Zibo,Liao YumeiORCID,Li Ying,Lin Qiongzhen,Hu Wenbo,Li Yulin,Zheng Zhaoxia,Duan Liping,Fu Gang,Guo Shanshan,Zhang Beiru,Yu Rui,Sun Fuyun,Ma Xiaoying,Hao Li,Liu Guiling,Zhao Zhanzheng,Xiao Jing,Shen Yulan,Zhang Yong,Du Xuanyi,Ji Tianrong,Wang CailiORCID,Deng Lirong,Yue Yingli,Chen Shanshan,Ma ZhigangORCID,Li Yingping,Zuo Li,Zhao Huiping,Zhang Xianchao,Wang Xuejian,Liu Yirong,Gao Xinying,Chen Xiaoli,Li Hongyi,Du Shutong,Zhao Cui,Xu Zhonggao,Zhang Li,Chen Hongyu,Li Li,Wang Lihua,Yan Yan,Ma YingchunORCID,Wei YuanyuanORCID,Zhou Jingwei,Li Yan,Zheng Yingdong,Wang Jinwei,Zhao Minghui,Dong Jie,

Abstract

<b><i>Introduction:</i></b> Telemedicine (TM) has shown to provide potential benefits on clinical outcomes in patients with chronic kidney disease but limited evidences published in the peritoneal dialysis (PD) population. This study aimed to explore the long-term effects of TM on the mortality and technique failure. <b><i>Methods:</i></b> The Peritoneal Dialysis Telemedicine-assisted Platform Cohort Study (PDTAP Study) was conducted prospectively in 27 hospitals in China since 2016. Patient and practice data were collected through the doctor-end of the TM app (Manburs) for all participants. TM including self-monitoring records, on-line education materials, and real-time physician-patient contact was only performed for the patient-end users of the Manburs. The primary outcome was all-cause mortality. The secondary outcomes were cause-specific mortality and all-cause and cause-specific permanent transfer to hemodialysis. <b><i>Results:</i></b> A total of 7,539 PD patients were enrolled between June 2016 and April 2019, with follow-up till December 2020. Patients were divided into two cohorts: TM group (39.1%) and non-TM group (60.9%). A propensity score was used to create 2,160 matched pairs in which the baseline covariates were well-balanced. There were significantly lower risks of all-cause mortality (HR 0.59 [0.51, 0.67], <i>p</i> &#x3c; 0.001), CVD mortality (HR 0.59 [0.49, 0.70], <i>p</i> &#x3c; 0.001), all-cause transfer to hemodialysis (0.57 [0.48, 0.67], <i>p</i> &#x3c; 0.001), transfer to hemodialysis from PD-related infection (0.67 [0.51, 0.88], <i>p</i> = 0.003), severe fluid overload (0.40 [0.30, 0.55], <i>p</i> &#x3c; 0.001), inadequate solute clearance (0.49 [0.26, 0.92], <i>p</i> = 0.026), and catheter-related noninfectious complications (0.41 [0.17, 0.97], <i>p</i> = 0.041) in the TM group compared with the non-TM group. <b><i>Conclusion:</i></b> This study indicated real-world associations between TM usage and reduction in patient survival and technique survival through a multicenter prospective cohort.

Publisher

S. Karger AG

Subject

Nephrology

Reference43 articles.

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3